Communiqués Apogee Therapeutics, Inc.

Actions

APGE

US03770N1019

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 21:57:39 14/08/2026			Varia. 5j.	Varia. 1 janv.
134,55 ^USD	+0,07%		-0,22%	+78,26%

12/08	Apogee Therapeutics, Inc. : BTIG passe à neutre sur le dossier	ZM
11/08	Apogee Therapeutics, Inc. annonce des changements au sein de son conseil d'administration et de ses comités	CI

Communiqués

10/08	Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates	AQ
30/07	Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE	BU
24/06	Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE	BU
22/06	APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders	BU
28/05	Apogee Therapeutics to Participate in Upcoming June Conferences	AQ
27/05	Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart	AQ
27/05	Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis	AQ
26/05	Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026	AQ
11/05	Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results	AQ
26/03	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million	AQ
25/03	Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering	AQ
23/03	Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering	AQ
23/03	Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis	AQ
23/03	Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026	AQ
02/03	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results	AQ
24/02	Apogee Therapeutics to Participate in Upcoming March Conferences	AQ
05/02	Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026	AQ
07/01	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart, its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma	AQ
06/01	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook	AQ
05/01	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026	AQ
10/11	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results	AQ
10/11	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody	AQ
03/11	Apogee Therapeutics to Participate in Upcoming Conferences	AQ
13/10/25	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million	AQ
10/10/25	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million	AQ